O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer
- 31 August 2003
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 41, S36
- https://doi.org/10.1016/s0169-5002(03)91770-3
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: